2. >>R&D

Cytokinetics’ CK-274 Appears To Upstage BMS’s Newly Acquired Mavacamten

Phase III Trial To Start By Year’s End

 
• By Mandy Jackson

The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.

Cardiology vector illustration; cardiomyopathy
Echocardiograms at multiple timepoints showed efficacy in both CK-274 cohorts • Source: Alamy

Cytokinetics, Inc. reported results from the 41-patient Phase II REDWOOD-HCM clinical trial on 19 July that appear to show better efficacy and improved safety with the cardiac myosin inhibitor CK-274 in the treatment of obstructive hypertrophic cardiomyopathy (oHCM) relative to mavacamten, a similar drug now owned by Bristol Myers Squibb Company that is under US Food and Drug Administration review with an approval decision expected in January.

The placebo-controlled REDWOOD-HCM trial was conducted to assess safety and efficacy in oHCM patients and to identify a range of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

More from R&D